Threshold Pharmaceuticals, Inc. Announces Phase 1/2 Interim Data Signaling Activity Of TH-302 Plus Bevacizumab (Avastin(R)) In Patients With Glioblastoma

Press/Media: Press / Media

PeriodNov 19 2014

Media coverage

1

Media coverage

  • TitleThreshold Pharmaceuticals, Inc. Announces Phase 1/2 Interim Data Signaling Activity Of TH-302 Plus Bevacizumab (Avastin(R)) In Patients With Glioblastoma
    Media name/outletBioSpace
    CountryUnited States
    Date11/19/14
    PersonsAndrew Brenner